Tivic Health Systems, INC 8-K filings

Tivic Health Systems has terminated its sublease agreement, effective May 31, 2024, and expects to save approximately $200,000 in lease expenses over the next 18 months.

Tivic Health has entered into a collaboration with the Feinstein Institutes for Medical Research to advance its non-invasive cervical vagus nerve stimulation (ncVNS) technology.

Tivic Health announced its Q1 2024 financial results, showing improved gross profit and reduced operating loss, alongside progress in their non-invasive vagus nerve stimulation program.

Tivic Health Systems has successfully closed a $4 million public offering, issuing common stock and warrants to investors.

Tivic Health's pilot study demonstrates significant biological changes using non-invasive vagus nerve stimulation, showing potential for clinical applications.

Tivic Health reported a decrease in revenue for 2023, alongside cost-cutting measures and strategic investments in new product development.

Tivic Health Systems announced the immediate termination of Chief Operating Officer Ryan Sabia, effective January 22, 2024.